EMA approves eight biosimilars

EMA approves eight biosimilars

The European Commission (EC) granted marketing authorization for eight biosimilars: Biocon’s Yesintek,Celltrion’s Avtozma, Eydenzelt, Osenvelt and Stoboclo; Samsung Bioepis’ Obodence and Xbryk, and CuraTeQ Biologics’ Zefylti in February 2025. The eight biosimilars approved by the EC include one aflibercept, four denosumab, one…